摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(氯甲基)-1-甲基-1H-咪唑盐酸盐 | 78667-04-6

中文名称
2-(氯甲基)-1-甲基-1H-咪唑盐酸盐
中文别名
1-甲基-2-(氯甲基)咪唑盐酸盐;2-氯甲基-1-甲基-咪唑盐酸盐;2-氯甲基-1-甲基-1h-咪唑盐酸盐
英文名称
2-chloromethyl-1-methyl-imidazol hydrochloride
英文别名
2-chloromethyl-1-methyl-1H-imidazole hydrochloride;2-(chloromethyl)-1-methylimidazole hydrochloride;1-methyl-2-chloromethylimidazole hydrochloride;2-(chloromethyl)-3-methyl-1H-imidazol-3-ium;chloride
2-(氯甲基)-1-甲基-1H-咪唑盐酸盐化学式
CAS
78667-04-6
化学式
C5H7ClN2*ClH
mdl
MFCD00234118
分子量
167.038
InChiKey
JDIPKQBKSBWIKU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    175 °C

计算性质

  • 辛醇/水分配系数(LogP):
    0.74
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    17.8
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 危险品标志:
    C
  • 安全说明:
    S26,S36/37/39,S45
  • 危险类别码:
    R34
  • 海关编码:
    2933290090
  • 包装等级:
    II
  • 危险类别:
    8
  • 危险性防范说明:
    P260,P264,P270,P280,P301+P330+P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P363,P405,P501
  • 危险品运输编号:
    3261
  • 危险性描述:
    H302,H314
  • 储存条件:
    室温和干燥环境下使用。

SDS

SDS:5d0eec9b4748b56e4f741536c91ac165
查看
Name: 2-(Chloromethyl)-1-methyl-1h-imidazole hydrochloride 97% Material Safety Data Sheet
Synonym:
CAS: 78667-04-6
Section 1 - Chemical Product MSDS Name:2-(Chloromethyl)-1-methyl-1h-imidazole hydrochloride 97% Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
78667-04-6 2-(Chloromethyl)-1-methyl-1H-imidazole 97% unlisted
Hazard Symbols: C
Risk Phrases: 34

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 78667-04-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 150 deg C(decom)
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H7ClN2
Molecular Weight: 167.04

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 78667-04-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(Chloromethyl)-1-methyl-1H-imidazole hydrochloride - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, N.O.S.*
Hazard Class: 8
UN Number: 1759
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, N.O.S.
Hazard Class: 8
UN Number: 1759
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, N.O.S.
Hazard Class: 8
UN Number: 1759
Packing group: III

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 78667-04-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 78667-04-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 78667-04-6 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    2-(氯甲基)-1-甲基-1H-咪唑盐酸盐sodium hydroxide 作用下, 以 甲醇 为溶剂, 生成 3-methyl-4-[[(1-methylimidazol-2-yl)methyl]sulfanyl]aniline
    参考文献:
    名称:
    BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
    摘要:
    本发明提供了一种新型的苯并氮杂环衍生物,其由以下公式表示: 其中,R1是一个5-或6-成员的芳香环,R2是低级烷基团等,Y是可选地取代的亚氨基,环A和环B是独立地选自一个可选地取代的芳香环,W是公式-W1-X2-W2-(W1和W2是独立地为S(O)m1(m1是0、1或2)等,X2是一个可选地取代的亚烷基团等),其制备方法及其用途。
    公开号:
    EP1422228A1
  • 作为产物:
    描述:
    1-甲基-2-羟甲基-1H-咪唑氯化亚砜 作用下, 反应 0.25h, 以85%的产率得到2-(氯甲基)-1-甲基-1H-咪唑盐酸盐
    参考文献:
    名称:
    可逆的丙烯酸化镍催化的分子间和分子内芳基硫醚的复分解反应。
    摘要:
    已经开发出镍催化的芳基硫醚复分解反应来获得高价值的硫醚。1,2-双(二环己基膦基)乙烷(dcype)对于促进这种高度官能团耐受的反应至关重要。此外,在不涉及烯键的闭环易位的不寻常实例中,可以高收率获得具有合成挑战性的大环化合物。深入的有机金属研究支持产物形成的可逆Ni0 / NiII途径。总体而言,这项工作不仅为以前的基于Pd的催化体系提供了更可持续的替代方法,而且还提出了与异常单键易位反应的进一步开发和应用高度相关的新应用和机理信息。
    DOI:
    10.1002/anie.201910436
点击查看最新优质反应信息

文献信息

  • Nickel-Catalyzed Reversible Functional Group Metathesis between Aryl Nitriles and Aryl Thioethers
    作者:Tristan Delcaillau、Philip Boehm、Bill Morandi
    DOI:10.1021/jacs.1c00529
    日期:2021.3.17
    We describe a new functional group metathesis between aryl nitriles and aryl thioethers. The catalytic system nickel/dcype is essential to achieve this fully reversible transformation in good to excellent yields. Furthermore, the cyanide- and thiol-free reaction shows high functional group tolerance and great efficiency for the late-stage derivatization of commercial molecules. Finally, synthetic applications
    我们描述了芳基腈和芳基硫醚之间的新官能团复分解。催化系统镍/dcype 对于实现这种完全可逆的转化,以良好的收率至关重要。此外,不含氰化物和硫醇的反应显示出高官能团耐受性和商业分子后期衍生化的高效率。最后,合成应用证明了它在多步合成中的多功能性和实用性。
  • [EN] FUSED RING COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS CYCLIQUES CONDENSÉS ET UTILISATION DE CEUX-CI
    申请人:TAKEDA PHARMACEUTICAL
    公开号:WO2009125873A1
    公开(公告)日:2009-10-15
    The present invention aims to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. The present invention provides a glucokinase activator containing a compound represented by the formula (I): wherein each symbol is defined in the specification, or a salt thereof or a prodrug thereof.
    本发明旨在提供一种葡萄糖激酶激活剂,可用作药用剂,如用于预防或治疗糖尿病、肥胖等疾病的药剂。本发明提供一种包含由式(I)表示的化合物的葡萄糖激酶激活剂:其中每个符号在规范中有定义,或其盐或前药。
  • FLAP MODULATORS
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:US20140221310A1
    公开(公告)日:2014-08-07
    The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R 1 , L and R 2 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.
    本发明涉及式(I)化合物,或其形式,其中环A,R1,L和R2如本文所定义,作为FLAP调节剂有用。该发明还涉及包含式(I)化合物的药物组合物。制备和使用式(I)化合物的方法也属于本发明的范围。
  • [EN] BICYCLIC INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS BICYCLIQUES DE L'HISTONE DÉSACÉTYLASE
    申请人:RODIN THERAPEUTICS INC
    公开号:WO2020014602A1
    公开(公告)日:2020-01-16
    Provided herein are compounds of Formula I and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone deacetylases (HDAC).
    本文提供了公式I的化合物及其药用盐和组合物,这些化合物对治疗与组蛋白去乙酰化酶(HDAC)相关的各种疾病条件有用。
  • [EN] PYRAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIMIDIN-2-YLE UTILISÉS COMME INHIBITEURS DE JAK
    申请人:ALMIRALL SA
    公开号:WO2015086693A1
    公开(公告)日:2015-06-18
    New pyrazolopyridmiin-2-yl derivatives are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
    新的吡唑吡啶-2-基衍生物被披露;以及它们的制备方法,包含它们的药物组合物以及它们作为Janus激酶(JAK)抑制剂在治疗中的用途。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺